KBC Group NV Cuts Stake in Avantor, Inc. (NYSE:AVTR)

KBC Group NV trimmed its position in Avantor, Inc. (NYSE:AVTR - Free Report) by 17.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 312,431 shares of the company's stock after selling 66,564 shares during the quarter. KBC Group NV's holdings in Avantor were worth $6,583,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB grew its holdings in Avantor by 99.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company's stock valued at $26,000 after buying an additional 625 shares in the last quarter. UMB Bank n.a. purchased a new stake in Avantor during the 3rd quarter valued at approximately $49,000. Nisa Investment Advisors LLC grew its holdings in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after buying an additional 835 shares in the last quarter. GAMMA Investing LLC grew its holdings in Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock valued at $70,000 after buying an additional 1,285 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of Avantor by 278.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company's stock valued at $130,000 after acquiring an additional 3,700 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AVTR shares. UBS Group reiterated a "neutral" rating and set a $25.00 target price (down from $29.00) on shares of Avantor in a research report on Friday, January 17th. Wells Fargo & Company lowered their target price on Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Monday, October 28th. Barclays lowered their target price on Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Friday, October 25th. Raymond James lowered their target price on Avantor from $29.00 to $26.00 and set an "outperform" rating for the company in a research report on Tuesday, January 21st. Finally, Robert W. Baird lowered their target price on Avantor from $27.00 to $26.00 and set an "outperform" rating for the company in a research report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, Avantor has a consensus rating of "Moderate Buy" and an average price target of $27.38.

Avantor Stock Up 3.4 %

Shares of AVTR opened at $22.22 on Friday. The company has a market cap of $15.12 billion, a PE ratio of 48.29, a P/E/G ratio of 3.53 and a beta of 1.28. The business has a fifty day moving average of $21.63 and a 200 day moving average of $23.43. Avantor, Inc. has a 52-week low of $19.59 and a 52-week high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.